Ivermectin has New Application Fighting Cancer Cell Growth

Published on October 9, 2021Written by frontiersin.org

Colorectal cancer (CRC) is the third most common cancer worldwide and still lacks effective therapy. Ivermectin, an antiparasitic drug, has been shown to possess anti-inflammation, anti-virus, and antitumor properties.

However, whether ivermectin affects CRC is still unclear.
The objective of this study was to evaluate the influence of ivermectin on CRC using CRC cell lines SW480 and SW1116. We used CCK-8 assay to determine the cell viability, used an optical microscope to measure cell morphology, used Annexin V-FITC/7-AAD kit to determine cell apoptosis, used Caspase 3/7 Activity Apoptosis Assay Kit to evaluate Caspase 3/7 activity, used Western blot to determine apoptosis-associated protein expression, and used flow cytometry and fluorescence microscope to determine the reactive oxygen species (ROS) levels and cell cycle.
The results demonstrated that ivermectin dose-dependently inhibited colorectal cancer SW480 and SW1116 cell growth, followed by promoting cell apoptosis and increasing Caspase-3/7 activity. Besides, ivermectin upregulated the expression of proapoptotic proteins Bax and cleaved PARP and downregulated antiapoptotic protein Bcl-2. Mechanism analysis showed that ivermectin promoted both total and mitochondrial ROS production in a dose-dependent manner, which could be eliminated by administering N-acetyl-l-cysteine (NAC) in CRC cells.
Following NAC treatment, the inhibition of cell growth induced by ivermectin was reversed. Finally, ivermectin at low doses (2.5 and 5 µM) induced CRC cell arrest. Overall, ivermectin suppressed cell proliferation by promoting ROS-mediated mitochondrial apoptosis pathway and inducing S phase arrest in CRC cells, suggesting that ivermectin might be a new potential anticancer drug therapy for human colorectal cancer and other cancers.
Colorectal cancer (CRC) refers to malignant tumors in the ascending colon, transverse colon, descending colon, sigmoid colon, and rectum and is one of the most common malignant tumors worldwide. Among all malignant tumors globally, CRC ranks third in incidence and second in mortality (Siegel et al., 2020). CRC has caused a heavy economic burden on the country and individuals (Maida et al., 2017).
At present, the treatment of CRC mainly adopts a comprehensive treatment based on surgery, combined with radiotherapy, chemotherapy, targeted therapy, and other treatments (Modest et al., 2019). However, due to the complicated mechanism of the occurrence, development, and metastasis of CRC, there is still a lack of specific drugs for CRC treatment.
Ivermectin is a derivative of the 16-membered macrolide compound abamectin, which was first widely used in clinical practice as an antiparasitic drug (Laing et al., 2017). Ivermectin can increase the activity of γ-aminobutyric acid receptor or glutamate-chloride ion channel (Glu-Cl), increase the influx of chloride ions, and cause the cell membrane hyperpolarization, thereby blocking signal transmission between neurons and muscles (Martin et al., 2021), which exerts its antiparasitic effects.
Ivermectin could be used, in addition to as an antiparasitic drug, as antiviral agents such as Flavivirus, HIV-1 virus, and SARS-CoV-2 virus (Mastrangelo et al., 2012; Wagstaff et al., 2012; Caly et al., 2020). Moreover, studies have shown that ivermectin has an inhibitory effect on various tumor cells and may be a potential broad-spectrum antitumor drug (Juarez et al., 2020). Juarez et al. (2020) have demonstrated that ivermectin is the most sensitive to breast cancer cells MDA-MB-231, MDA-MB-468, MCF-7, and ovarian SKOV-3; whereas ivermectin is the most nonsensitive to the prostate cancer cell line DU145.
The induction of cell cycle arrest at G0/G1 mediates this effect of ivermectin on these sensitive cancer cells. Furthermore, ivermectin can inhibit the proliferation of cancer cells through p21-activated kinase 1 (PAK1)-induced autophagy, Caspase-dependent apoptosis, or immunogenic cell death regulate the signal pathways, including Hippo, Akt/mTOR, and WNT-TCF pathways to inhibit cancer cell proliferation (Liu et al., 2020).
As known, ROS plays a vital role in the apoptosis caused by oxidative stress. ROS is a by-product of normal mitochondrial respiration. Stimuli such as infection, drought, cold, and ultraviolet light result in increased ROS in cells. Then, accumulative ROS could induce cells mitochondrial dysfunction and promote apoptosis in cells (Sinha et al., 2013). Evidence has shown that ivermectin-induced apoptosis is closely related to the production of ROS. Currently, there are few reports on the research of ivermectin in colorectal cancer.
Furthermore, new use of old drugs (that is, drug relocation) is a strategy for expanding old drugs and developing new uses, which has the advantages of low research and development cost and short development time (Pushpakom et al., 2019). Research on drug relocation of ivermectin is a shortcut to developing new antitumor drugs. Given this, we designed a study to explore the impact of ivermectin on the proliferation and apoptosis of CRC cells and the underlying mechanism.
Materials and Methods
Cell Culture
SW480 and SW1116 cells were acquired from ATCC and grown in DMEM medium (Biological Industries, Israel) supplemented with 10 percent FBS (Biological Industries, Israel), 1 percent penicillin/streptomycin (Coolaber, Beijing, China), and 2.5 percent HEPES buffer (Procell, Wuhan, China) in an incubator with a humidified air atmosphere of 5% CO2 at 37°C.
Cell Viability Assay
Cells were seeded at a density of 1 × 104 cells/well in a 96-well plate. After being cultured overnight, cells were treated with ivermectin (Figure 1) (MCE Chemicals, Shanghai, China) at the indicated concentrations for 12, 24, or 36 h or cells were pretreated with N-Acetyl-l-cysteine (NAC, 5 mM) (Aladdin, Shanghai, China) for 1 h and then were cultured in ivermectin (20 μM) for 6 h.
Then, 10 μL of CCK-8 solution was added to each well and incubated at 37°C for 1 h. The absorbance was detected at 450 nm by a microplate reader (SpectraMax i3x, Molecular Devices, United States). The cell viability was calculated as follows: (absorbance of drug-treated sample/absorbance of control sample) × 100.
Cell Morphology
Colorectal cancer cells were plated at 1 × 105 cells/well in twelve-well plates. After being cultured overnight, the cells were treated with ivermectin at the indicated dose for 24 h. Cell morphology was evaluated using an optical microscope.
Flow Cytometry
Apoptosis was determined using the Annexin V-FITC/7-AAD Apoptosis Kit. Briefly, after colorectal cancer cells were exposed to ivermectin (0, 5, 10, and 20 μM) for 6 h, cells were centrifuged at 1,500 rpm for 5 min, washed, and suspended in PBS. Then, cells were stained with Annexin V-FITC and 7-AAD for 15 min. In addition, cells (1 × 106 cells/well) were cultured onto 6-well plates overnight and treated with indicated concentrations (0, 2.5, 5, and 10 μM) of ivermectin.
Then, the cells were harvested and resuspended in PBS and fixed with 70% ethanol, and left at −20°C overnight. After 12 h of fixation, cells were centrifuged, washed, and resuspended in cold PBS. Then, the cells were added with 100 μL of RNase and incubated at 37°C for 30 min. The PI staining solution was then added and incubated at 4°C for 30 min. Cells were acquired by flow cytometry (FACSCanto Plus), and data were analyzed using Flowjo 10.0 software.
The percentage of Q2 (early apoptosis, Annexin V+7-AAD–) plus Q3 (late apoptosis, Annexin V+7-AAD+) region was counted as the percentage of apoptosis cells.
Caspase 3/7 Activity Assay
Caspase 3/7 assay was performed using the Caspase 3/7 Activity Apoptosis Assay Kit (Sangon Biotech, Shanghai, China). Briefly, after colorectal cancer cells (SW480 or SW1116) were treated with different concentrations of ivermectin (0, 5, 10, and 20 μM) for 6 h, we added 100 μL of Caspase 3/7 reagent into each well and mixed using a plate shaker. The Caspase 3/7 activity was then determined using a microplate reader (SpectraMax i3x). The Caspase 3/7 activity was expressed as a fold of the untreated control (Con) treatment.
Western Blot Assay
After colorectal cancer cells (SW480 and SW1116) were treated with 0, 5, and 10 μM ivermectin for 6 h, they were collected, washed with PBS, and lysed with RIPA buffer. Protein quantification was determined using BCA Protein Assay Kit (EpiZyme Biotechnology, Shanghai, China). Equal amounts of protein were loaded onto an SDS-PAGE gel for electrophoresis and transferred to nitrocellulose.
After blocking with 5% nonfat milk for 1 h, the membranes were incubated with the primary antibody [Bcl-2 (1:2000), Bax (1:2000), PARP (1:20,000) (all from Proteintech, Rosemont, IL, United States), and β-actin (1:5000) (Sigma-Aldrich)] on a 4°C shaker overnight. The membranes were then incubated with a secondary antibody for another 1 h at room temperature. A chemiluminescent gel imaging system detected the change in target protein expression (Universal Hood II, Bio-Rad, Hercules, CA, United States).
ROS Measurement
For total ROS measurement, colorectal cancer cells (SW1116) were seeded (1 × 105 cells/well) in a 12-well plate and incubated overnight. Cells were treated with different concentrations of ivermectin for another 6 h, and then they were co-cultured with DCFH-DA (Invitrogen, Carlsbad, CA, United States) and DAPI (Biolegend, San Diego, CA, United States) for 20 min at 37°C in the dark. The cell fluorescence was photographed by fluorescence microscopy (OLYMPUS, Tokyo, Japan).
For the mitochondrial ROS measurement, colorectal cancer cells (SW1116) were seeded in a 12-well plate and incubated overnight. After that, cells were treated with 0, 2.5, 5, 10, and 20 μM ivermectin for another 6 h, and then they were tinted with oxidation of MitoSOX Red (Invitrogen, Carlsbad, CA) and DAPI, which is oxidized by superoxide in the mitochondria, emitting red fluorescence.
Cultures were incubated for 10 min at 37°C and washed twice with warm HBSS. Production of mitochondrial ROS was analyzed using MitoSOX Red. The cell fluorescence was photographed by fluorescence microscopy.
Data Analysis
All experiments were repeated at least three times, and data were presented as mean ± S.E.M. The statistics were analyzed using a one-way or two-way ANOVA analysis (ANOVA) followed by Tukey’s test using Prism 9.0 software (Graphpad Software). p values are *, p < 0.05, #, p < 0.05; Results Ivermectin Inhibits the Proliferation of Colorectal Cancer Cells To explore the effect of ivermectin on the proliferation of colorectal cancer cells, we used different concentrations of ivermectin (0, 2.5, 5, 10, 15, 20, and 30 μM) to culture colorectal cancer cells SW480 and SW1116. CCK-8 assay was performed to measure SW480 and SW1116 cancer cell proliferation after cells were incubated for 12, 24, and 36 h. As shown in Figure 2, the cell viability of SW480 and SW1116 cells decreased dose-dependently by ivermectin treatment (Dose, D: p < 0.01). Furthermore, ivermectin inhibited SW480 and SW1116 cell viability in a time-dependent manner (Time, T: p < 0.01). Finally, Table 1 showed that the IC50 of SW480 cells treated with ivermectin for 12, 24, and 36 h was 16.17 ± 0.76 μM, 15.34 ± 0.81 μM, and 12.11 ± 0.97 μM, respectively; and the IC50 of SW1116 cells treated with ivermectin for 12, 24, and 36 h were 7.60 ± 0.62 μM, 6.27 ± 0.70 μM and 5.76 ± 0.81 μM, respectively. The present data indicate that ivermectin might have more sensitive to SW1116 cells than that of SW480 cells. Ivermectin Changes the Morphology of Colorectal Cancer Cells To study the impact of ivermectin on the cell morphology of colorectal cancer cells, we treated colorectal cancer cells SW480 and SW1116 with different concentrations of ivermectin and then observed the alteration of cell morphology under an optical microscope. After 24 h culture, the cell morphology changed significantly. For the SW480 cells, as the ivermectin concentration increased, the cells became more and more sparse. Especially at 20 μM, the cells lost their original shape, became rounded, and shrunk or floated in the medium (Figure 3). Consistent with IC50 of ivermectin, ivermectin had more sensitivity to SW1116 cells since ivermectin at 5 μM resulted in the cells shrunk; when the concentration of ivermectin was 10 μM, the cells became round, shrunk, and floated in the medium, and the concentration of ivermectin increased to 20 μM, most of the cells shed and floated in the culture medium (Figure 3). These results suggest that ivermectin could promote the death of colorectal cancer cells in a dose-dependent manner. Ivermectin Induces Apoptosis in Colorectal Cancer Cells To determine whether ivermectin decreased the cell viability and the cell morphology of colorectal cancer cells via inducing cell apoptosis, we cultured colorectal cancer cells SW480 and SW1116 cells with indicated concentrations of ivermectin for 6 h, and apoptosis was evaluated by flow cytometry using Annexin V-FITC/7-AAD co-staining. As shown in Figure 4, ivermectin increased the proportion of apoptosis cells of SW1116 cells from 9.48 percent in the control group to 10.5 percent, 19.87 percent, and 30.5 percent in 5, 10, and 20 μM, respectively. Like this, ivermectin increased the proportion of apoptosis SW480 cells from 4.65 percent in the control cells to 8.51, 12.27, and 12.66 percent in 5, 10, and 20 μM, respectively. The results indicated that ivermectin had a dose-dependent effect on the induction of colorectal cancer cell apoptosis. Ivermectin Increases Caspase 3/7 Activity in SW480 and SW1116 Cells Caspase-3 plays a vital role in the initiation of cell apoptosis. Caspase-3 typically exists in the cytoplasm in the form of zymogen (32KD). Caspase-3 activated by upstream signaling molecules can cleave the downstream key apoptosis proteins in the early stages of apoptosis and ultimately lead to apoptosis. In this study, the Caspase 3/7 Activity Apoptosis Assay kit was used to determine the effect of ivermectin on cell apoptosis. As shown in Figure 5, ivermectin increased Caspase 3/7 activity of SW480 and SW1116 cells in a dose-dependent manner. Ivermectin Affects the Expression of Apoptosis-Related Proteins in SW480 and SW1116 Cells Bax and Bcl-2 are critical molecules in the endogenous apoptotic pathway. PARP (poly ADP-ribose polymerase) is a DNA repair enzyme, cleaved into Cleaved-PARP by the Caspase family protein, and cannot perform the repair function. The Western blot assay was used to determine the changes of apoptosis-related proteins Bax, Bcl-2, PARP, and Cleaved-PARP after treatment of colorectal cancer SW480 and SW1116 cells with ivermectin at the indicated doses. As the concentration of ivermectin increased, the expression of the proapoptotic protein Bax increased significantly, and the expression of the antiapoptotic protein Bcl-2 decreased; that is, the expression of the Bax/Bcl-2 ratio was gradually increasing (Figure 6). Also, the expression of Cleaved-PARP increased following the increase of ivermectin concentration (Figure 6). This is taken from a very long document. Read the rest here: frontiersin.org Header image: Medpage Today Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.  Related Trackback from your site.

NASA Awards X-59 Quiet Supersonic Flight Community Testing contract

Published on October 9, 2021Written by progressiveengineer.com

NASA has selected Harris Miller Miller & Hanson (HMMH) to support a national campaign of community overflight tests with NASA’s X-59 Quiet SuperSonic Technology research aircraft.

NASA’s X-59 Community Response Testing will assess the potential effects on communities from noise emissions from the supersonic aircraft.
The agency’s vital work in advancing the science behind supersonic flight will pave the way for new entrants to the National Airspace System.
This cost-plus-fixed-fee, indefinite-delivery/indefinite-quantity contract has a maximum potential value of approximately $29 million with an eight-year period of performance.
The scope of the work under this contract includes supporting NASA in the planning, execution, and documentation of phase three of the agency’s Low-Boom Flight Demonstration mission.
NASA will provide the results of the community survey and the X-59 acoustic data collected during the community overflight tests to U.S. and international regulators for use in considering new sound-based rules to enable supersonic flight over land.
NASA is designing and building the X-59 research aircraft – a piloted, single-seat supersonic X-plane – with technology that reduces the loudness of a sonic boom to that of a gentle thump.
NASA’s aeronautical innovators are leading a team across government and industry to collect data that could allow supersonic flight over land, dramatically reducing travel time within the United States or to anywhere in the world.
NASA currently is working with Lockheed Martin Skunk Works of Palmdale, California, to design, build, and conduct initial flight testing of the X-59 research aircraft as part of phase one of the mission.
The team will work during phase two to prove the X-59 performs as designed and is safe to fly in the national airspace.
During phase three, NASA will fly the X-59 aircraft over communities yet to be selected and ask residents to share their response to the sound the aircraft generates during supersonic flight.
HMMH will work with several subcontractors on the project, including Blue Ridge Research and Consulting of Asheville, North Carolina; Westat of Rockville, Maryland; EMS Brüel & Kjær of Folsom, California dba Envirosuite; the Center for Atmospheric Sciences (CAS) at Hampton University; Spire Global; Senzig Engineering; and Crown Consulting.
HMMH was founded in 1981 to provide noise consulting services to airports.
Headquartered in Burlington, Massachusetts the consulting firm has other offices in Virginia, California, and New York. Today, HMMH is an international player in environmental and transportation planning including noise and vibration control, air quality analysis, airport and airspace planning, and sustainable energy solutions.
See more here:progressiveengineer.com
Header image: CNET
Editor’s note: Is it just me, or does this aircraft remind you of the Icarus from the original Planet of the Apes?

Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 


Trackback from your site.

Researchers to build biosensor capable of measuring nutrients in water

Published on October 9, 2021Written by progressiveengineer.com

The surface of a pristine, transparent freshwater lake may not reveal to ecologists the reality of what’s occurring in its depths.

Evaluating various cumulative effects such as pollutants or invasive species requires more precise methods. But even the most dynamic and sensitive sensors commonly used today can’t always tell researchers what they need to know.
Engineers at Rensselaer Polytechnic Institute (RPI) are teaming up with an unexpected ally, a metal-breathing bacterium called Shewanella oneidensis MR1 (S. oneidensis), to try to dramatically improve biosensors for freshwater and marine aquatic ecosystems.
In a new project, a research team will build biosensors using bacteria that can sense and communicate levels of nutrients in a body of water with enhanced levels of sensitivity, scalability, and versatility.
The effort, supported by a nearly $375,000 grant from the National Science Foundation, is being led by Shayla Sawyer, an associate professor of electrical, computer, and systems engineering at Rensselaer.
The concept builds upon previous and promising research Sawyer and her lab have already done with S. oneidensis. Researchers demonstrated that when this unique bacterium “breathes” in certain metal and sulfur compounds anaerobically, it produces nanowires capable of transferring electrons.
Sawyer found that, because their electronic signatures can be mapped and monitored, bacterial biofilms could “collect” data and then connect to — and communicate with — an electronic device. (You can watch Sawyer discuss this research here.)
Sawyer and her lab will now integrate S. oneidensis with E. coli to sense and measure even more nutrients in an environment. Because E. coli can more easily be genetically modified, it can be used to sense a broader array of nutrients in an environment. It will then “communicate” that information to the S. oneidensis, which will be connected to the electronic side of the sensor, feeding data back to researchers.
“Previously, we worked with S. oneidensis detecting phosphate as a test case. Now, we’re looking at more nutrients that E. coli could target potentially, and introducing it in a larger system,” Sawyer says. “If we can create that interface, than maybe we can measure multiple targets at once.”
Sawyer will work with Jonathan Dordick, an endowed chair professor of chemical and biological engineering at Rensselaer, on the genetic modifications necessary for E. coli to be used in this biosensor. Once the sensor is developed, the team will test and validate its accuracy.
Depending on what researchers find, this approach could be used to measure the health of other environments, too.
“There’s also some implication that we can do this in soil, so we could potentially do this for agriculture, which means it could become a more versatile environmental sensor,” Sawyer says. “This is a starting point for how we could possibly modify bacteria to do more things.”
This research also includes an educational outreach component, as graduate students will create learning modules for undergraduates who will create materials for K-12 students in the Capital Region.
Local students working with the Sanctuary for Independent Media Nature Lab will create educational content for students at the H20 Virtual academy at the Karanda Mixed Secondary School in Kisumu, Kenya.
“The goals of the research are reflected in how we intend to involve communities. We will establish an international connection of gifted local and international students, like a flow of intellectual stimuli, to convey state-of-the-art knowledge about the environment around them,” Sawyer states.
See more here: progressiveengineer.com
Header image: US News
Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 


Trackback from your site.

James Webb Telescope Will ‘Change How We See the Universe’

Published on October 9, 2021Written by thevintagenews.com

NASA is preparing for the December launch of the James Webb Telescope, after former NASA administrator James Webb, it will use infrared technology to examine far-away planets.

The launch of the Webb Telescope was originally set to occur in 2010, but delays forced NASA to push it back to December 2021. After successfully completing a series of rigorous tests, the launch is set to occur on December 18, 2021 from Europe’s Spaceport in French Guiana, on the northeastern coast of South America.
NASA is working in partnership with the European and Canadian space agencies for the launch. The telescope will be launched on an Ariane 5, from which it will detach 10,400 kilometers into the journey. Moments after separating, its solar-powered array will unfold, supplying electricity to the telescope.
This process includes 178 release mechanisms working to allow it to complete its 40 major deployments. Once in space, Webb will wait 35 days after launch before aligning its mirrors. It is estimated the first images collected by the telescope will be released to the public in summer 2022, some six months after.
“Webb is an exemplary mission that signifies the epitome of perseverance,” said Gregory L. Robinson, Webb’s program director at NASA Headquarters in Washington. “I am inspired by our team and our global partnerships that have made this incredible endeavor possible. Together, we’ve overcome technical obstacles along the way, as well as challenges during the coronavirus pandemic. I also am grateful for the steadfast support of Congress.
“Now that we have an observatory and a rocket ready for launch, I am looking forward to the big day and the amazing science to come,” he added.
The telescope has a 21-feet-long light-collecting mirror covered in gold, which will catch the light and allow scientists to analyze the chemical makeup of the planets’ atmospheres. It’s divided into segments, and it and a five-layer, tennis court-sized sun shield can fold inside a rocket and later unfurl.
The mirror is the most important aspect of Webb, as it is optimized to see near- and mid-infrared light invisible to the human eye. This differs from the Hubble Telescope, which only shows optical light humans can see. An infrared telescope like Webb can not only see older and colder objects, but it also has the ability to see through the dust that obscures stars and other objects in the images transmitted from Hubble.
This is key, as it will allow scientists to see tell-tale combinations of different gases – known as “biosignatures” – such as oxygen and methane.
“The James Webb Space Telescope does have the capability to measure those key biosignatures,” said Nikole Lewis, an astronomer at Cornell University. “It’s within scope for the James Webb Space Telescope to find hints of life on rocky planets.”
NASA isn’t calling Webb a replacement for Hubble, rather an extension of what it’s accomplished. While Hubble orbits the earth at 570 kilometers above, Webb will sit 1.5 million kilometers away, at the Earth-Sun L2 Lagrange point. The L2 is the region where the gravitational pull from the earth and the sun balance to create the ideal long-term position for telescopes.
From this location, Webb will be able to study planets outside of our solar system, as well as light that has been traveling for almost the entire history of the universe.
“Webb will reveal new and unexpected discoveries, and help mankind understand the origins of the universe and our place in it,” said NASA in a statement.
The idea for the Webb Telescope came about over three decades ago, and its construction involved 1,200 scientists, engineers, and technicians from 14 countries and more than 28 U.S. states. The aim was to build a telescope that could capture light emanating from the first galaxies in the universe, and the effort has cost $10 billion.
It is the largest space telescope in history, and is estimated to be 100 times more powerful than Hubble.
See more here: thevintagenews.com
Header image: NASA
Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 


Trackback from your site.

Dear Parents: Tired of watching your child walk?

Published on October 9, 2021Written by theexpose.uk

Then why not let them join the 1,149 people left paralysed by the Covid-19 Vaccine?

Dear parents,
Are you aware that 86 percent of children suffered an adverse reaction to the Pfizer Covid-19 vaccine in the extremely short and small clinical trial? (source)
Are you aware that 1 in 9 children suffered a serious adverse reaction leaving them unable to perform daily activities in the extremely short and small clinical trial? (source)
Are you aware that up to August 25th 2021, just nine deaths associated with Covid-19 had occurred in children since March 2020? (source)
Are you aware that the risk of children developing serious illness due to Covid-19 is extremely low? (source)
Are you aware the Pfizer Covid-19 vaccine is experimental and still in clinical trials? (source)
Are you aware three scientific studies conducted by the UK Government, Oxford University, and CDC, which were published in August 2021, have found the Covid-19 vaccines do not work? (source)
Are you aware that Public Health England data shows the majority of Covid-19 deaths are among the vaccinated, and the data suggests the vaccines worsen disease? (source)
Are you aware there have been more deaths in 8 months due to the Covid-19 vaccines that there have been due to all other available vaccines since the year 2001? (source)
Are you aware of the real risk of myocarditis (heart inflammation) in children due to the Pfizer vaccine? (source)
Are you aware children are dying due to the Covid-19 vaccines in the USA? (source)
Are you aware of who profits from your child getting the Covid-19 vaccine? (source)
Are you aware the Joint Committee on Vaccination & Immunisation refused to recommend the Pfizer vaccine be offered to children, and are you aware they were overruled by Chris Whitty, the Chief Medical Officer for England? (source)
Are you aware that since teenagers were first offered the Covid-19 vaccine that deaths among 15 – 19-year-olds have increased by 47 percent on the previous year? (source)
If you were not aware of any of these things, then you are now. But if you still decide despite all of the above that you would like your child to get the Covid-19 vaccine then it must be because you are tired of watching your child walk, and you’d like them to join the other 1,149 people that have been left paralysed by the Covid-19 vaccines in the UK?
The latest report on adverse reactions to the Covid-19 vaccines reported to the MHRA Yellow Card scheme reveals that up to September 22nd 2021 a total of 323 reports of paralysis were made against the Pfizer mRNA vaccine.
These include 11 reports of diplegia, 41 reports of hemiparesis, 36 reports of himplegia, 1 report of locked-in-syndrome, 48 reports of monoparesis, 63 reports of monoplegia, 112 reports of full paralysis, 3 reports of paraparesis, 6 reports of paresis, 1 report of quadriparesis, and 1 report of quadriplegia.
A further 778 reports were also made to the MHRA against the AstraZeneca vaccine, including 111 reports of hemiparesis, 100 reports of monoparesis, 138 reports of monoplegia, and 324 reports of full paralysis resulting in 1 death.
The MHRA also received 42 reports of paralysis due to the Moderna vaccine, with 9 reports of monoparesis, 12 reports of monoplegia, and 11 reports of full paralsyis.
Whilst a further 6 reports of paralsyis were made to the MHRA where the brand of vaccine was not specified.
If you’re not tired of watching your child walk then perhaps you are tired of them having the ability to see? So why not let them get the Covid-19 vaccine so they can join the other 417 people left completely blind by the Covid-19 vaccines? Or the 1,075 people left with impaired vision?
If the possibility your child might be left paralysed, or lose their vision, or both, isn’t enough for you though then perhaps you just want your child to die, and join the other 1,682 people who have lost their lives due to the Covid-19 vaccines?
Including 544 people who last their lives to the Pfizer injection, alongside the 330,983 injuries that it has caused up to September 22nd.
1,091 people who have lost their lives to the AstraZeneca injection alongside the 828,941 injuries it has caused.
19 people who have lost their lives to the Moderna injection alongside the 52,344 injuries it has caused.
And 28 people who have lost their lives where the brand of vaccine was not specified in the report made to the MHRA, alongside 3,329 injuries where the brand of vaccine was also not specified.
You may not get what you wish for of course parents, as not every person is being left blind, paralysed, or losing their life due to the Covid-19 vaccines. However, with a total of 1,215,597 injuries being reported, and approximately 48.6 million people having been vaccinated, at least there is a 1 in 39 chance that your child will suffer an injury due to the Covid-19 vaccine.
A chance that is more likely 1 in 4, because just 10 percent of adverse reactions are reported to the MHRA Yellow Card scheme.
See more here: theexpose
Header image: CNN
Bold emphasis added
Please Donate Below To Support Our Ongoing Work To Expose The Lies About COVID19
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 


Trackback from your site.

Merck Claims “Phenomenal” Test Results For Experimental COVID Pill

Published on October 9, 2021Written by zerohedge.com

Merck announced Friday that an experimental COVID pill it has developed reduced hospitalizations and deaths by 50 percent in people recently infected with COVID.

The company will soon ask health officials in the US and abroad to authorize use of the drug.
The news came as a welcome surprise to the public, although COVID cases are already waning in the US and in hard-hit economies in Asia, the drug could create “a real therapeutic advance” that could dramatically decrease the risk of death from COVID.
If approved (and odds are it will be) the drug would be the first treatment for COVID. Some compared it to tamiflu, in that patients should take it within 5 days of COVID infection (like those infected with the flu are instructed to take tamiflu early).
Former FDA Director Dr. Scott Gottlieb told CNBC that the trial results are clearly “profoundly” positive, even though researchers decided to stop the trial early because the drug showed significant success, meaning it would be unethical to keep giving patients placebos.
To test the drug, they needed to test more than 700 unvaccinated people in a global study. The people were all considered in the “high risk” category due to factors like age, and other characteristics from their “health profile”.
Per the results, seven percent of volunteers in the group that received the drug were hospitalized, and none of them died, compared with a 14 percent rate of hospitalization and death (include eight who died) in the placebo group.
According to Dr. Gottlieb, “this is a phenomenal result. This is a profound game-changer that we have an oral pill that had this kind of effect on patients who are already symptomatic.”
Dr. Gottlieb also pointed out that the team that developed the drug “also invented the first successful antibody against ebola so this is a very good drug-development team.”
“And remember we have two other drugs in development one by Pfizer (where Dr. Gottlieb serves on the board) and the other by Roches,” he said.
Patients won’t be taking the drug for very long, typically around five days, which means “the safety profile is probably pretty good,” Dr. Gottlieb said.
Per the NYT,
“the Merck pill’s efficacy was lower than that of monoclonal antibody treatments, which mimic antibodies that the immune system generates naturally when fighting the virus. Those drugs have been in high demand recently, but they are expensive, are typically given intravenously, and have proved cumbersome and labor-intensive for hospitals and clinics to administer. Studies have shown that they reduce hospitalizations and deaths 70 to 85 percent in similar high-risk Covid patients.”
The Merck drug is significantly chemically different from the Pfizer drug that’s in its final round of studies, which means there’s the possibility of creating a cocktail of anti-viral treatments for COVID.
Merck has said it can produce 10MM pills by the end of this year, and Dr. Gottlieb said he expects they’ll ramp up production quickly by partnering with other companies.
Merck partnered with a small firm called Ridgeback Biotherapeutics to develop the drug, which is called Molnupiravir.
While the study results haven’t yet been peer reviewed, at least one independent group of medical experts have given the research their blessing.
“This is a milestone in the fight against COVID,” Dr. Gottlieb said.
So, is the prospect of a return to “normality” really on the table? I suppose we’re about to find out.
See more here: zerohedge.com
Please Donate Below To Support Our Ongoing Work To Expose The Lies About COVID19
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 


Trackback from your site.

California to Require COVID Vaccine for Students to Attend School

Published on October 9, 2021Written by theepochtimes.com

California students will be required to receive the COVID-19 vaccine to attend school once the vaccines have received full approval by the Federal Food and Drug Administration (FDA), Gov. Gavin Newsom announced on Oct 1.

The government has fully approved the COVID-19 vaccine for individuals ages 16 and older, meaning all upper-class high school students will need to be fully vaccinated to attend both public and private schools.
Only an emergency authorization has been granted for anyone 12 to 15. When the FDA approves the vaccine for that age group, students in seventh grade and up also be required to get vaccinated. The requirement is foreseen to be implemented in the next term, either Jan. 1 or July 1 of 2022.
“What we are announcing here today, a statewide requirement for in-person instruction for all of our children to add to a well-established list that currently includes ten vaccinations and well-established rules and regulations that have been advanced by the legislator for decades. To add to that list, the vaccination for COVID-19, we intend to do that once the FDA has fully approved the vaccine which will give us time to work with districts,” Newsom said during an Oct. 1 press conference.
The governor announced the vaccine mandate at the San Francisco Unified School District alongside state Sen. Scott Wiener, a Democrat.
The governor further announced staff working in K-12 schools will also be required to be vaccinated, and eventually everyone once FDA approval is granted for students in K-6.
Newsom said religious and medical exemptions will be permitted under the state’s mandate.
Wiener applauded the governor’s effort in combating the COVID-19 virus within schools.
“The legislator has shown over and over again that we are willing to pass strong vaccination laws, and if we have to come back and do it again next year, we will do that,” Wiener said.
However, the move drew criticism from some.
Mari Barke, Chair of the Orange County Board of Education, said that it should be up to parents to decide what is best for children.
“I’m certainly not proud that California is the first state to mandate this. I think parents are the best to make these types of decisions for their children, so I’m very disappointed,” Barke told The Epoch Times. “I believe strongly in parental rights and parents knowing what’s best for their children. This vaccine has had the least testing of any vaccine. It’s not a virus that is killing lots of children unless they have severe co-morbidities, and I think it’s government overreach.”
Barke said that due to this measure, she believes a lot of parents will be taking their children out of school in order to homeschool them. Many parents do not want their children masked in school, let alone vaccinated, she added.
“I really think you’re going to see a huge amount of children coming out of schools and being homeschooled,” she said. “We’re not in a state of emergency. We’re not in one for adults, never mind children.”
Jon Schrank, a parent of a student within Tustin Unified School District, said that he feels the move is “typical government overreach.”
“[The mandate is] not unexpected. As soon as Newsom won the recall, we all sort of knew that all these little things were going to start to come about from him,” Schrank told The Epoch Times.
“My opinion is, it’s typical government overreach. I’m not an anti-vaxxer. I’m pro-choice, and that’s your business, it’s not my business. So, the fact that they’re making this happen for a bunch of kids that have no risk of really getting terribly ill from it [is not good.]”
Schrank said that those who are for the mandate will argue that the students will spread it to the adults who are more vulnerable, but that if the adults are vaccinated, that should take care of the problem.
“If you’re worried about it, get the vaccination, that’s your business,” he said. “I don’t think we need to have the government telling us what we need to do with our children. That’s my point of view if I want to get the vaccine for my kid, then I would do it. If I don’t want to do it, that should be my choice … It’s no longer about personal choice, it’s about government intervention.”
Schrank added that the mandate will likely only force parents to put their children back into virtual education like last year, which caused many students to fall behind.
As of Oct. 1, California has administered one dose to 63.5 percent of youth ages 12 to 17, but the governor is aiming for the new requirements to create more of an advanced incentive.
“There is still a struggle to get where we need to go,” Newsom said. “That means we need to do more, and we need to do better … we have continued to lead … California was the first state to require statewide school mask-wearing requirements. We were first in America to require all of our staff to either be vaccinated and or get weekly testing.”
See more here: theepochtimes.com
Header image: John Fredricks
Please Donate Below To Support Our Ongoing Work To Expose The Lies About COVID19
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 


Trackback from your site.



By Kris Vallotton

24 Sep, 2021

Have you ever been faced with a problem that feels impossible to solve? The kind that grieves your heart, brings worry to your mind, and leaves you lying awake as you think of all the ways there could be resolve? There are problems that feel miles deep and cycles that feel generations long that leave even the experts left uncertain of how to move along. I’d propose even with our best effort and intent we will not solve the world’s most pressing problems if we limit our thinking to earthly thoughts. If you have been on the earth for much time at all you have probably faced a few challenging circumstances. Challenges can wear us out, and drag us down, but I would propose that God uses the challenges in our lives to prepare us for our divine destiny! In the Kingdom of God ashes turn to beauty and takes our challenges and turns them to victories. The challenge is many Believers feel dismayed because they don’t realize the power they have access to. It is clear that we must be aware of where the problem is coming from. What I am getting at is there is a first, second, and third Heaven. In Genesis 1 the first Heaven was created — this is the visible world, the dimensions that our five senses are acutely tuned in to. Then we see mentioned in 2 Corinthians 12:2 that Paul was taken up to the third Heaven. Paul reveals through his own spiritual experience that there is a third heaven two levels above our earthly experience and one level above the spiritual realm. This leaves us with a mention of the first and third Heaven, so what does the second Heaven entail? In Ephesians 6:12 we know “ our fight is not against flesh and blood, but against principalities, against powers, and against spiritual forces of wickedness in the Heavenly places. ” Notice that the apostle Paul said that there are evil forces in heavenly places. Let’s be clear: There are no demonic, satanic or evil forces in the third heaven. Thus, we call this realm from which Satan rules the second heaven. We are not going to solve a first heaven problem that was caused by second heaven devils, without taking our third heaven seat. Ephesians 2:4 says that we have been seated in heavenly places. But, so often we get stuck on first Heaven problems without seeking third Heaven solutions. It is time to adjust our thinking, grab hold of our authority in Christ, and lean into the solution available to us as Believers. Many Christians have a third Heaven experience where the impossible becomes possible as God busts through the door and lays His divine hand on the situation; paving the way for a miracle, curing the illness before our eyes, or opening doors that were bolted shut in our lives. The challenge is, when we come up against another impossible situation, we sometimes forget the eternal power that changed everything! For example, one day we experience the supernatural power of God in our lives; we see him feed the 5,000, heal the leper, raise the dead and the next day we are panicked trying to solve all our problems in our own strength. But, what if third heaven solutions were our first line of defense? Fear keeps us on our earthly seat, but faith places us on our Heavenly throne. What if problems became our faith builders and terrible situations increased our strength? I encourage you to watch this week’s video blog as I share further about the first, second, third Heaven, and how as Believers we can access Heavenly solutions.

Police capture Texas high school shooter, who later posts bail

Following the mass shooting in Arlington, Texas Wednesday, police captured the gunman Timothy George Simpkins. Simpkins shot two people at Timberview High School around 9:15 AM. After drawing and firing his weapon, Simpkins fled the scene. Police arrested him after he reportedly turned himself in. This came hours into his manhunt. Now, they expect to charge … Read more